Finally had a change to read this properly ( not easy to read earlier on my phone ).
Awesome work.
Fabulous best in class, first in class analysis. Interesting angle on risk for a buyer with Bisantrene having a massive head start ( which will only make a buyer more keen to achieve a deal outcome ).
The strong efficacy of Bisantrene compared to efficacy of the other agents subject to M&A transactions is striking. Whilst most were first in class their efficacy data was weak. I had not looked at this in my peer analysis ( just focused on the value ).
Finally had a change to read this properly ( not easy to read...
-
- There are more pages in this discussion • 827 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.045(2.86%) |
Mkt cap ! $260.8M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $157.5K | 102.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3901 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.54 | 1000 | 1 |
View Market Depth
| Last trade - 15.03pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |